The regulatory distinction you made is so crucial: the July FDA advisory committee meeting on BPC-157, TB-500, KPV, and others is about compounding access through the 503A pathway, not approval, and not evidence of efficacy
Anti-inflammatory NF-B Modulation MC1R and MC3R activation by melanocortin peptides has been shown to suppress NF-B nuclear translocation and downregulate pro-inflammatory cytokine production (TNF-, IL-6, IL-1) in macrophage and keratinocyte models, suggesting a role in cutaneous inflammatory signaling research (Luger et al., Journal of Investigative Dermatology, 1997)
Side effects beyond nausea , including anxiety in some patients, often resolve after the body adjusts to each new dose level
Hu Y, Benya RV, Carroll RE, Diamond AM